Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Ibrutinib, a covalent BTK inhibitor, was the first B-cell receptor (BCR) inhibitor approved for the treatment of CLL and other B-cell malignancies. It binds irreversibly to Bruton's tyrosine kinase (BTK), blocking its activity and preventing downstream signaling.
…